Skip to Main Content

The Department of Veterans Affairs has decided not to cover a new Alzheimer’s drug from Biogen (BIIB), citing insufficient evidence of “a robust and meaningful clinical benefit” and concerns about safety, according to a notice issued by the agency.

However, the VA said it will make exceptions for “highly selected patients” and listed several hurdles that must be cleared before the medicine will be covered, such as requiring it to be prescribed by providers who specialize in treating dementia and ensuring patients had recently received MRI brain scans.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment